Gianpaolo Fogliatto’s Post

View profile for Gianpaolo Fogliatto, graphic

Sr. Business Development Director | Drug Discovery Europe | Charles River Laboratories

“Captain T Cell is devoted to developing a new generation of toolbox-engineered T cell-based immunotherapies for solid tumor patients. We have the utmost confidence in the expertise of Charles River as we work to bring our lead candidate to the clinic.” Felix Lorenz, CEO, Captain T Cell Once infused into a patient’s body, these tumor-specific T cells seek to find and destroy tumor cells and may provide an alternative for patients with tumors that no longer respond to other therapies. Read the story in full: https://okt.to/irxNMq #genemodifiedcelltherapy #genetherapy #tcelltherapy #immunotherapy #viralvectors

  • An Award-winning Approach to Cancer Immunotherapy

To view or add a comment, sign in

Explore topics